AIMA
GTHX

Ables Iannone Moore & Associates’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Ables Iannone Moore & Associates’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,732
Closed -$14.4K – 303
2023
Q4 		$14.4K Buy
+4,732
New +$8.89K 0.01% 162

Other funds holding GTHX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ables Iannone Moore & Associates's GTHX Position: Q1 2024 in Review

Ables Iannone Moore & Associates sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2024, closing a stake of 4,732 shares — an estimated $14.4K sold.

Ables Iannone Moore & Associates first reported a position in GTHX in Q4 2023 and held it in 1 quarter. The position peaked at $14.4K in Q4 2023. 86 funds tracked by Wall St. Rank hold GTHX as of Q1 2024.

  • Ables Iannone Moore & Associates reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Ables Iannone Moore & Associates sold 4,732 G1 Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $14.4K.
  • Ables Iannone Moore & Associates first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Ables Iannone Moore & Associates's G1 Therapeutics, Inc. Common Stock position peaked at $14.4K in Q4 2023.
  • 86 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Ables Iannone Moore & Associates's 13F filing for Q1 2024, filed 30 Apr 2024.